Evidence map›Paper›PMID 27063654›Full record

ArticleCancer research and treatment2016

Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer.

Guiyun Sohn, Sei Hyun Ahn, Hee Jeong Kim, Byung-Ho Son, Jong Won Lee, Beom Seok Ko, Yura Lee, Sae Byul Lee, Seunghee Baek

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Guiyun SohnDivision of Breast and Endocrine Surgery, Departments of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sei Hyun AhnDivision of Breast and Endocrine Surgery, Departments of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hee Jeong KimDivision of Breast and Endocrine Surgery, Departments of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Byung-Ho SonDivision of Breast and Endocrine Surgery, Departments of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jong Won LeeDivision of Breast and Endocrine Surgery, Departments of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Beom Seok KoDivision of Breast and Endocrine Surgery, Departments of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yura LeeDivision of Breast and Endocrine Surgery, Departments of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sae Byul LeeDivision of Breast and Endocrine Surgery, Departments of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Seunghee BaekDepartment of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Asan Medical Center · KRUniversity of Ulsan · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to compare treatment outcomes between combined gonadotropin-releasing hormone agonist and tamoxifen (GnRHa+T) and sequential adriamycin and cyclophosphamide chemotherapy and tamoxifen (AC->T) in premenopausal patients with hormone-responsive, lymph-node-negative breast cancer. MATERIALS AND

methodsIn total, 994 premenopausal women with T1-T2, lymph-node-negative, hormone-receptor-positive, HER2-negative breast cancer between January 2003 and December 2008 were included in this retrospective cohort study. GnRHa+T and AC->T were administered to 608 patients (61.2%) and 386 patients (38.8%), respectively. Propensity score matching and inverse probability weighting were applied to the original cohort, and 260 patients for each treatment arm were included in the final analysis. Recurrence-free, cancer-specific, and overall survival was compared between the two treatment groups.

resultsA total of 994 patients were followed up for a median of 7.4 years (range, 0.5 to 11.4 years). The 5-year follow-up rate was 98.7%, and 13 patients were lost to follow-up. In propensity-matched cohorts (n=520), there was no difference in recurrence-free, cancer-specific, and overall survival rates between the two treatment groups (p=0.306, p=0.212, and p=0.102, respectively), and this was maintained after applying inverse probability weighting.

conclusionGnRHa+T is a reasonable alternative to AC->T in patients with premenopausal, hormone-responsive, HER2-negative, lymph-node-negative, T1-T2 breast cancer.

Indexed as

AdultAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDisease-Free SurvivalDoxorubicinErb-b2 Receptor Tyrosine KinasesFemaleGonadotropin-Releasing HormoneHumansLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPremenopauseAntineoplastic Agents, HormonalCyclophosphamideDoxorubicinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGonadotropin-Releasing HormoneTamoxifenBreast neoplasmsChemotherapyDrug therapyPremenopauseTamoxifen

Identifiers

PMID27063654
PMCPMC5080815
OpenAlexW2328527366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.